CHEMOTHERAPY SEPT. 1992 cefoperazone ceftazidime (CAZ), imipenem (IPM) Staphylococcus sp., Enterococcus (CPZ), faecalis, Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii, Enterobacter cloacae, Serratia sp., Proteus mirabilis, Proteus vulgaris, Pseudomonas aeruginosa Serratia marcescens, Pseudomonas aeruginosa phylococcus sp., Enterococcus faecalis, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Proteus vulgaris, Enterobacter cloacae, Citrobacter P.aeruginosa, Acinetobacter calcoa- Enterobacter sp., Citrobacter sp. freundii, Serratia sp., P.aeruj inosa
Staphylococcus sp. K.pneumoniae P.mirabilis C.freundii E. cloacae Serratia sp. P. aeruginosa ml, Enterococcus avium >100ƒÊg/ml
CHEMOTHERAPY Table 1. In vitro antibacterial activity of cefclidin against clinical isolates Inoculum size: 106 CFU/ml
VOL.40 S-4 Table 2. Clinical summary of complicated UTI patients treated with cefclidin CCP: chronic complicated pyelonephritis CCC: chronic complicated cystitis VUR: vesicoureteral reflex HAM: HTL V-1 associated myelopathy * before treatment after treatment ** UTI: criteria proposed by the UTI Committee Dr.: Dr's evaluation
CHEMOTHERAPY SEPT. 1992 Table 3. Overall clinical efficacy of cefclidin in complicated UTI Bacteriological response * regardless of bacterial count Table 4. Overall clinical efficacy of cefclidin classified by the type of infection K.pneumoniae, C.freundii, E. cloacae, P. aeruginosa
Table 5. Bacteriological response to cefclidin in complicated UTI *regardless of bacterial count Table 6. Strains*appearing after cefclidin treatment in complicated UTI *regardless of bacterial count YLO: yeast like organism
CHEMOTHERAPY Table 7. Relation between MIC and bacteriological response to cefclidin treatment in complicated UTI No. of strains eradicated/no. of strains isolated Table 8. Changes in laboratory test results 8) Collatz E et al: Developement of resistance to 3) Watanabe N, Katsu K, Moriyama M, and Kitoh K: In vitro evaluation of E1040, a new cephalosporin with potent antipseudomonal activity. Antimicrob Agent Chemother 32: 693 `701, 1988 7) Spratt BG, Pardee AB: Penicillin bin ding protein and cell shape in E.coli. Nature 254: 516,1975 beta-lactam antibiotics with specific referens to third generation cephalosporins. Antimicrob Chemother 14 (B): 13,1984
VOL.40 S-4 9) Yokota T: Methicillin and cephemresistant Staphylococcus aureus. Infect Inflam Immun 14: 87,1984 ANTIMICROBIAL ACTIVITIES AND CLINICAL STUDIES ON CEFCLIDIN IN COMPLICATED URINARY TRACT INFECTION Kazuya Kawahara, Motoshi Kawahara, Yoshihiro Mizuma, Shinichi Makinose Toshihiro Gotou, Nichiro Sakamoto and Yoshitada Ohi Department of Urology, Faculty of Medicine, Kagoshima University 8-35-1, Sakuragaoka, Kagoshima 890, Japan Antimicrobial activities and clinical studies on cefclidin (CFCL), a new injectable cephalosporin, were performed and the following results were obtained. 1. Antibacterial activity of cefclidin Antibacterial activity of CFCL against 10 kinds of urinary pathogenic bacteria consisting of each 30 strains from urine were studied and compared to cefoperazone (CPZ), ceftazidime (CAZ) and imipenem(ipm). As to the antibacterial activities against Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii, Enterobacter cloacae and Pseudomonas aeruginosa, CFCL was superior to the other drugs. Against Proteus mirabilis and Proteus vulgaris, CFCL showed weaker activities than CAZ, but stronger activities than both IPM and CPZ. Antibacterial activity of CFCL was inferior to CAZ and IPM against Serratia marcescens. 2. Clinical efficacy CFCL was administered in a daily dose of 1.0g or 2.0g for five consecutive days to 15 cases by i. v. or drip infusion. The overall clinical efficacy rate was 86.7% (13/15). 3. Bacteriological response 22 of 23 strains (95.7%) isolated from patients with urinary tract infection including 5 of Grampositive cocci and Gram-negative rods were eradicated. 4. Adverse reaction No severe adverse reactions and abnormal laboratory findings or ophthalmologic disorders was observed.